BIIB34:BVMF
Biogen Inc BDR
R$230.10
0.00%
(0.00) 1D
Nov 4, 3:38:07 PM GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Mkt. cap
36.71B
Avg. vol.
9.00
Volume
0.00
52-wk high
R$230.10
52-wk low
R$137.90
Shares outstanding
147.82M
No. of employees
8K
Mkt. cap
36.71B
Avg. vol.
9.00
Volume
0.00
52-wk high
R$230.10
52-wk low
R$137.90
Shares outstanding
147.82M
No. of employees
8K
News stories
From web sources and news partners
BigGo Finance
·
2 hours ago
VIX Jumps 11.57 Points in a Day as S&P 500 Drops 4.41%; Historical Data Shows 79% Positive Returns Six Months Later
Reuters Connect
·
15 hours ago
A screen displays the Dow Jones Industrial Average after the closing bell on the floor of the NYSE in New York
qz.com
·
21 hours ago
Stock futures explained: how Dow, S&P 500 and Nasdaq-100 contracts work
StoneX
·
1 day ago
S&P 500 Forecast: SPX rebounds after strong NFP led by tech
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websitebiogen.com